Compare Stocks: RLMD, GHRS, CMPS, and ETON

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPS Compass Pathways	$13.27 -0.2%	$13.10	$4.82 ▼ $15.40	$1.84B	2.54	2.29 million shs	788,565 shs
ETON Eton Pharmaceuticals	$58.45 -2.4%	$47.78	$14.27 ▼ $66.37	$1.67B	0.9	696,454 shs	521,365 shs
GHRS GH Research	$28.23 +1.1%	$28.15	$11.83 ▼ $31.44	$1.94B	1.27	274,582 shs	78,097 shs
RLMD Relmada Therapeutics	$4.43 +1.4%	$5.29	$1.30 ▼ $8.00	$472.55M	0.45	1.08 million shs	675,553 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPS Compass Pathways	-0.15%	-3.35%	-2.28%	+9.58%	+181.74%
ETON Eton Pharmaceuticals	-2.42%	-2.22%	+27.15%	+100.65%	+234.96%
GHRS GH Research	+1.11%	+1.04%	-3.09%	+31.73%	+101.36%
RLMD Relmada Therapeutics	+1.37%	+2.31%	-18.57%	-25.55%	+201.36%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPS Compass Pathways	$13.27 -0.2%	$13.10	$4.82 ▼ $15.40	$1.84B	2.54	2.29 million shs	788,565 shs
ETON Eton Pharmaceuticals	$58.45 -2.4%	$47.78	$14.27 ▼ $66.37	$1.67B	0.9	696,454 shs	521,365 shs
GHRS GH Research	$28.23 +1.1%	$28.15	$11.83 ▼ $31.44	$1.94B	1.27	274,582 shs	78,097 shs
RLMD Relmada Therapeutics	$4.43 +1.4%	$5.29	$1.30 ▼ $8.00	$472.55M	0.45	1.08 million shs	675,553 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPS Compass Pathways	-0.15%	-3.35%	-2.28%	+9.58%	+181.74%
ETON Eton Pharmaceuticals	-2.42%	-2.22%	+27.15%	+100.65%	+234.96%
GHRS GH Research	+1.11%	+1.04%	-3.09%	+31.73%	+101.36%
RLMD Relmada Therapeutics	+1.37%	+2.31%	-18.57%	-25.55%	+201.36%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMPS Compass Pathways	2.88	Moderate Buy	$23.36	76.01% Upside
ETON Eton Pharmaceuticals	2.50	Moderate Buy	$67.50	15.48% Upside
GHRS GH Research	2.75	Moderate Buy	$45.00	59.40% Upside
RLMD Relmada Therapeutics	2.75	Moderate Buy	$12.00	170.88% Upside

Current Analyst Ratings Breakdown

Latest RLMD, GHRS, CMPS, and ETON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	ETON Eton Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/14/2026	ETON Eton Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$60.00 ➝ $68.00
8/14/2026	ETON Eton Pharmaceuticals	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00 ➝ $70.00
8/14/2026	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$65.00 ➝ $70.00
8/13/2026	GHRS GH Research	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/11/2026	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$57.00 ➝ $65.00
8/10/2026	GHRS GH Research	New Street Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$65.00
8/10/2026	GHRS GH Research	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/7/2026	GHRS GH Research	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$34.00 ➝ $40.00
8/7/2026	CMPS Compass Pathways	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$70.00 ➝ $65.00
8/7/2026	GHRS GH Research	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$35.00 ➝ $40.00

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMPS Compass Pathways	N/A	N/A	N/A	N/A	$0.61 per share	N/A
ETON Eton Pharmaceuticals	$105.60M	15.82	$0.01 per share	11,556.57	$1.63 per share	35.86
GHRS GH Research	N/A	N/A	N/A	N/A	$5.24 per share	N/A
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	$1.94 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMPS Compass Pathways	-$287.86M	-$4.62	N/A	N/A	N/A	N/A	-49.63%	-13.08%	11/3/2026 (Estimated)
ETON Eton Pharmaceuticals	-$4.60M	$0.38	153.82	30.13	N/A	12.02%	40.13%	12.37%	11/5/2026 (Estimated)
GHRS GH Research	-$48.26M	-$1.00	N/A	N/A	N/A	N/A	-20.86%	-20.12%	11/5/2026 (Estimated)
RLMD Relmada Therapeutics	-$57.38M	-$0.90	N/A	N/A	N/A	N/A	-47.52%	-43.97%	11/12/2026 (Estimated)

Latest RLMD, GHRS, CMPS, and ETON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ETON Eton Pharmaceuticals	$0.1898	$0.43	+$0.2402	$0.35	$27.11 million	$37.59 million
8/6/2026	Q2 2026	GHRS GH Research	-$0.2860	-$0.23	+$0.0560	-$0.23	N/A	N/A
8/6/2026	Q2 2026	RLMD Relmada Therapeutics	-$0.1995	-$0.11	+$0.0895	-$0.11	N/A	N/A
8/5/2026	Q2 2026	CMPS Compass Pathways	-$0.3881	-$1.88	-$1.4919	-$1.88	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMPS Compass Pathways	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	N/A
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMPS Compass Pathways	0.60	1.30	1.30
ETON Eton Pharmaceuticals	0.41	1.52	1.30
GHRS GH Research	N/A	28.70	28.70
RLMD Relmada Therapeutics	N/A	29.52	29.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMPS Compass Pathways	46.19%
ETON Eton Pharmaceuticals	27.86%
GHRS GH Research	56.90%
RLMD Relmada Therapeutics	45.24%

Insider Ownership

Company	Insider Ownership
CMPS Compass Pathways	2.82%
ETON Eton Pharmaceuticals	16.49%
GHRS GH Research	41.60%
RLMD Relmada Therapeutics	14.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMPS Compass Pathways	120	138.48 million	134.57 million	Optionable
ETON Eton Pharmaceuticals	20	28.58 million	23.87 million	Optionable
GHRS GH Research	10	68.61 million	40.07 million	Optionable
RLMD Relmada Therapeutics	10	106.67 million	91.20 million	Optionable

RLMD, GHRS, CMPS, and ETON Headlines

Recent News About These Companies

Seven Fleet Capital Management LP Takes $2.41 Million Position in Relmada Therapeutics, Inc. $RLMD

September 5 at 4:40 AM | marketbeat.com

Relmada’s NDV-01 Bladder Cancer Trial Moves Into Phase 3: What Investors Should Watch

September 2 at 12:50 PM | tipranks.com

Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference

September 1, 2026 | globenewswire.com

Corient Private Wealth LP Makes New Investment in Relmada Therapeutics, Inc. $RLMD

September 1, 2026 | marketbeat.com

BlackRock Inc. Makes New Investment in Relmada Therapeutics, Inc. $RLMD

September 1, 2026 | marketbeat.com

After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)

August 31, 2026 | zacks.com

After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)

August 31, 2026 | uk.finance.yahoo.com

Jupiter Topco LLC Invests $77.32 Million in Relmada Therapeutics, Inc. $RLMD

August 28, 2026 | marketbeat.com

Deutsche Bank AG Buys New Position in Relmada Therapeutics, Inc. $RLMD

August 28, 2026 | marketbeat.com

ADAR1 Capital Management LLC Takes Position in Relmada Therapeutics, Inc. $RLMD

August 26, 2026 | marketbeat.com

Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now

August 25, 2026 | zacks.com

6,391,328 Shares in Relmada Therapeutics, Inc. $RLMD Purchased by Spruce Street Capital LP

August 25, 2026 | marketbeat.com

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Receives Consensus Rating of "Moderate Buy" from Analysts

August 17, 2026 | marketbeat.com

616,238 Shares in Relmada Therapeutics, Inc. $RLMD Acquired by Walleye Capital LLC

August 15, 2026 | marketbeat.com

Relmada (RLMD) Q2 2026 Earnings Call Transcript

August 14, 2026 | finance.yahoo.com

Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround

August 11, 2026 | zacks.com

Equities Analysts Issue Forecasts for RLMD Q3 Earnings

August 11, 2026 | marketbeat.com

Relmada Therapeutics (NASDAQ:RLMD) Posts Quarterly Earnings Results, Beats Expectations By $0.09 EPS

August 8, 2026 | marketbeat.com

Relmada Therapeutics (NASDAQ:RLMD) Stock Price Down 6.8% - Time to Sell?

August 7, 2026 | marketbeat.com

Relmada Therapeutics Q2 Earnings Call Highlights

August 7, 2026 | marketbeat.com

Relmada Therapeutics, Inc. (RLMD) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLMD, GHRS, CMPS, and ETON Company Descriptions

Compass Pathways NASDAQ:CMPS

$13.27 -0.02 (-0.15%)

As of 09/4/2026 04:00 PM Eastern

Compass Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to Compass Pathways plc in August 2020. Compass Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Eton Pharmaceuticals NASDAQ:ETON

$58.45 -1.45 (-2.42%)

As of 09/4/2026 04:00 PM Eastern

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

GH Research NASDAQ:GHRS

$28.23 +0.31 (+1.11%)

As of 09/4/2026 04:00 PM Eastern

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Relmada Therapeutics NASDAQ:RLMD

$4.43 +0.06 (+1.37%)

As of 09/4/2026 04:00 PM Eastern

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RLMD, GHRS, CMPS, and ETON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RLMD, GHRS, CMPS, and ETON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RLMD, GHRS, CMPS, and ETON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLMD, GHRS, CMPS, and ETON Company Descriptions

Compass Pathways NASDAQ:CMPS

Eton Pharmaceuticals NASDAQ:ETON

GH Research NASDAQ:GHRS

Relmada Therapeutics NASDAQ:RLMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RLMD, GHRS, CMPS, and ETON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RLMD, GHRS, CMPS, and ETON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RLMD, GHRS, CMPS, and ETON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLMD, GHRS, CMPS, and ETON Company Descriptions

Compass Pathways NASDAQ:CMPS

Eton Pharmaceuticals NASDAQ:ETON

GH Research NASDAQ:GHRS

Relmada Therapeutics NASDAQ:RLMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools